1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 May 2022
Admin
News Article

Valneva Completes Lot To Lot Phase 3 Trial Of Single-Shot Chikungunya Vaccine Candidate

Valneva Se, A Specialty Vaccine Company, Announced The Successful Completion Of The Lot-To-Lot Phase 3 Trial Of Its Single-Shot Chikungunya Vaccine Candidate, Vla1553. The Final Analysis Included Six-Month Follow-Up Data And Confirmed The Topline Results Reported In December 2021.The Vla1553-302 Trial Met Its Primary Endpoint, Demonstrating That Three Consecutively Manufactured Vaccine Lots Elicited Equivalent Immune Responses Measured By Neutralizing Antibody Titer Gmt Ratios On Day 29 After Vaccination.The Trial Included 408 Participants Aged 18 To 45 Years. The Safety Profile Shown In Study Vla1553-302 Was Similar To The Phase 3 Trial, Vla1553-301. With A 96.0% Seroprotection Rate At Day 180, The Immunogenicity Profile From Study Vla1553-301 Was Also Confirmed.Juan Carlos Jaramillo, Chief Medical Officer Of Valneva Commented,

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!